

Oligonucleotide Therapeutics and Delivery: Half Day Pre – Conference Workshop

SMi Group reports: The 'Target Discovery for RNA Therapeutics' workshop will be taking place on Tuesday 15th September 2021 in London, UK.

LONDON, ENGLAND, UNITED KINGDOM, June 1, 2021 /EINPresswire.com/ -- SMi Group are delighted to announce that the Target Discovery for [RNA Therapeutics](#) workshop will be held on Tuesday 15th September 2021 at Holiday Inn Forum in London, UK. The workshop will highlight [Oligonucleotide Therapeutics](#) – the emerging medicine class and the therapeutic benefit of target genetic material via antisense, mRNA, RNAi, saRNA and siRNA. They bring about the ability to affect targets that have been considered “non - druggable”. Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies.

For those interested in attending this workshop, register by 30th June 2021 to save £100. Register at: www.oligonucleotide.co.uk/PR3.

Martine Akerman, Chief Technology Officer, Envisagenics will be running the Target Discovery for RNA Therapeutics. He is the inventor of the SpliceCore® platform, Envisagenics' flagship [AI technology](#) for the discovery of splicing-based therapeutic targets. He received his PhD in Bioinformatics from Technion, Israel Institute of Technology. As a first-time entrepreneur, Martin represented Envisagenics in winning the J&J AI for Drug Discovery QuickFire challenge in 2017 and Microsoft's Innovate.AI challenge in 2018. His goal is to combine cutting-edge computation with RNA domain expertise to develop innovative drugs for cancer and genetic diseases.

Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.

With this in mind, SMi group will be bringing together leading representatives of pharmaceutical, biotechnology and academic institutions to provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY.

The event brochure with the agenda and workshop line-up is available to download from the website; those interested in attending can register at: www.oligonucleotide.co.uk/PR3

Proudly Sponsored by ChemGenes | Genscript | Tosoh Bioscience

For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Jinna Sidhu

SMi Group

+442078276088 ext.

[email us here](#)

Visit us on social media:

[Twitter](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/542638181>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.